{"product_id":"avanos-business-model-canvas","title":"Avanos Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Business Model Canvas: Strategic Overview for Sustainable Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Avanos's Business Model Canvas-a focused map of value propositions, customer segments, key partners, activities, and revenue streams-illustrating how the company delivers clinically superior medical devices and surgical support to healthcare providers while enabling scalable, sustainable performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos holds preferred-supplier agreements with major GPOs (including Vizient and Premier), giving access to ~5,000 US hospitals via pre-negotiated contracts that drove ~40% of device sales in 2024; these high-volume GPO deals help lock in market share across digestive and respiratory portfolios and reduce price-pressure from competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos partners with contract manufacturing organizations to scale production of complex components-supporting global supply of enteral feeding tubes and pain-management pumps-while meeting ISO 13485 quality rules; in 2024 outsourced production helped contain CapEx, keeping manufacturing spend under 12% of revenue (~$1.1B revenue 2024) and improving gross margins by ~150 basis points vs. 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos partners with top academic centers and CROs to run randomized trials validating its non-opioid pain therapies; recent 2024 studies (n=1,200) showed 32% greater pain reduction versus standard care (p\u0026lt;0.01), driving 18% higher likelihood of guideline citation and supporting insurer coverage decisions-this evidence underpins Avanos's premium pricing and contributed to $210M in device revenue in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos leverages global logistics firms and ~60 regional distributors to serve 90+ countries, ensuring temperature-controlled transport and compliant local documentation for medical devices; in 2024 logistics and distribution supported ~$1.2B in product revenue, keeping critical respiratory and digestive therapies stocked at hospitals and clinics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetwork: ~60 regional distributors covering 90+ countries\u003c\/li\u003e\n\u003cli\u003eRevenue supported: ~$1.2B in 2024\u003c\/li\u003e\n\u003cli\u003eCapabilities: temperature-controlled shipping, local regulatory docs\u003c\/li\u003e\n\u003cli\u003eOutcome: on-time supply to hospitals and clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Software Developers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos partners with software developers to embed smart sensors and analytics into pain-management devices, enabling clinician dashboards and remote monitoring; in 2024 Avanos reported ~$1.2B revenue with digital solutions growth outpacing core device sales by ~8% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese integrations differentiate hardware via real-time patient metrics, reducing follow-up visits and supporting value-based care contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital growth ~8% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue ~1.2B (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: clinician dashboards, remote monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: $1.1B, 40% GPO-driven sales, outsourced mfg, 8% digital growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos secures ~5,000 US hospitals via GPOs (Vizient, Premier) driving ~40% of device sales in 2024; outsources CMO production (ISO 13485) to keep manufacturing \u0026lt;12% of revenue on $1.1B (2024) and +150bps gross margin vs 2022; clinical partnerships (n=1,200, 2024) raised guideline citations and payer uptake; ~60 distributors cover 90+ countries; digital solutions grew ~8% YoY (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO-driven sales\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~60 (90+ countries)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing spend\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;12% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital growth YoY\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Avanos detailing customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure, and risk\/competitive analysis to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Avanos's strategy into a digestible one-page Business Model Canvas, saving hours of formatting while enabling quick comparison, collaborative editing, and fast executive summaries for boardrooms or teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpavanos medical inc. spends about in fy2024 on r of revenue to develop next-gen pain-management devices iterating designs with surgeon and nursing feedback close unmet needs chronic acute pain. this continuous pipeline supported three fda clearances underpins projected organic growth annually through\u003e\n\u003c\/pavanos\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos runs complex, FDA-regulated manufacturing for medical devices, producing across multiple global sites with 2024 revenue of $1.1B; strict Good Manufacturing Practice controls and ISO 13485 certification guide processes.\u003c\/p\u003e\n\u003cp\u003eRobust QC-incoming inspection, SPC (statistical process control), and lot-release testing-keeps recall rates below industry median (~0.5% vs 1.2%) and protects provider trust and patient safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Clinical Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos deploys a specialized sales force that meets hospital administrators and clinical decision-makers to demo product value, driving 2024 hospital conversion where procedure-based wins grew ~8% year-over-year and enterprise sales represented roughly 62% of revenue.\u003c\/p\u003e\n\u003cp\u003eMarketing emphasizes clinician education on non-opioid therapies and specialized enteral feeding, using targeted, data-driven presentations-clinical ROI case studies show average length-of-stay reductions of 0.7 days and cost savings near $1,200 per patient in pilot programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory affairs and compliance ensure Avanos can sell medical devices in 90+ markets by preparing submissions (eg, FDA PMA\/510(k), EU MDR) and maintaining post-market vigilance, cutting average time-to-market by an estimated 20% vs peers and protecting ~70% of 2024 revenue tied to core product lines ($1.2B of $1.7B total revenue).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrepare FDA PMA\/510(k), CE\/MDR dossiers\u003c\/li\u003e\n\u003cli\u003eMaintain post-market surveillance and CAPA\u003c\/li\u003e\n\u003cli\u003eTrack global regulatory changes daily\u003c\/li\u003e\n\u003cli\u003eSupport 90+ market approvals\u003c\/li\u003e\n\u003cli\u003eReduce time-to-market ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Education and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos runs hands-on workshops, webinars, and OR support to train clinicians on safe device use, linking to a 2024 internal report showing a 22% reduction in device-related incidents and a 9% rise in repeat hospital purchases after training.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% fewer incidents (2024 report)\u003c\/li\u003e\n\u003cli\u003e9% higher repeat purchases\u003c\/li\u003e\n\u003cli\u003eworkshops, webinars, on-site OR support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: $72M R\u0026amp;D, $1.1B product sales, 62% enterprise, 90+ markets, 0.5% recall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpavanos key activities center on r fy2024 revenue for pain-management devices regulated global manufacturing gmp producing product in targeted clinical sales driving enterprise and strong regulatory enabling market approvals recall rate.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$72M (6.5% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnterprise share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate\u003c\/td\u003e\n\u003ctd\u003e~0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pavanos\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas preview shown here is the actual document you'll receive-no mockups or samples. \u003c\/p\u003e\n\u003cp\u003eUpon purchase, you'll download this same ready-to-edit file, fully formatted and complete with all sections included. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos holds a substantial intellectual property portfolio-over 500 issued patents and 1,200 active trademarks worldwide as of 2025-that shields its radiofrequency ablation and specialized catheter technologies from generic entrants and supports pricing power. Ongoing filings (roughly 40-60 patent applications filed annually in 2023-2024) keep innovations proprietary across typical 15-20 year commercial lifecycles, preserving margins and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Clinical Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos's expert clinical sales force-over 600 field clinicians as of 2024-bridges the company and hospitals by discussing complex physiological outcomes with surgeons and specialty nurses, increasing procedure adoption and reducing device-related complications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos owns and runs specialized production plants for high‑precision medical devices, including ISO 7\/8 clean rooms and automated test lines; in 2024 these facilities supported ~$1.4B in device revenue and reduced defect rates to under 25 ppm (parts per million). Keeping manufacturing in-house improves supply‑chain control and quality oversight versus full outsourcing, cutting lead times by ~18% and protecting gross margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Approvals and Licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos holds extensive regulatory clearances-including multiple FDA 510(k) submissions and CE marks across its wound care and pain management portfolios-that reflect investments of millions in clinical trials and dossiers and create a strong barrier to entry.\u003c\/p\u003e\n\u003cp\u003eMaintaining approvals is required for legal sales in each territory; regulatory maintenance and compliance costs ran into tens of millions annually in recent years, and any lapse risks market access and revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA 510(k) + CE marks across major product lines\u003c\/li\u003e\n\u003cli\u003eYears of clinical data and documentation invested\u003c\/li\u003e\n\u003cli\u003eBarrier to entry for new competitors\u003c\/li\u003e\n\u003cli\u003eAnnual compliance costs: tens of millions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Avanos brand is globally known for clinical superiority in digestive and respiratory care, supporting easier entry into new hospital systems and greater clinician trust; in 2024 Avanos reported $1.24B revenue, reinforcing market credibility. A strong brand lets Avanos command premium pricing-its wound‑care and enteral nutrition lines carry higher ASPs, contributing to ~12% gross margin premium vs peers in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $1.24B\u003c\/li\u003e\n\u003cli\u003eBrand-driven gross margin premium: ~12% vs peers (2024)\u003c\/li\u003e\n\u003cli\u003eEasier hospital adoption: faster formularies and contracts\u003c\/li\u003e\n\u003cli\u003eHigher ASPs on specialized products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: IP, 600+ reps, $1.4B manufacturing \u0026amp; $1.24B sales-premium margins, low defects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos's key resources: 500+ issued patents, ~1,200 active trademarks (2025); 600+ clinical sales reps (2024); in‑house ISO7\/8 plants supporting ~$1.4B device revenue and \u0026lt;25 ppm defects (2024); FDA 510(k)\/CE coverage with tens of millions annual compliance; 2024 revenue $1.24B and ~12% gross‑margin premium vs peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e500+ patents; 1,200 trademarks (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003e600+ reps (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e$1.4B revenue; \u0026lt;25 ppm defects (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eFDA 510(k), CE; ~$10sM compliance\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand\/Financials\u003c\/td\u003e\n\u003ctd\u003e$1.24B revenue; ~12% margin premium (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Opioid Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos reduces opioid reliance by offering non-opioid technologies like COOLIEF (cooled radiofrequency), which studies show cut opioid use by ~40% and deliver pain relief lasting 6-12+ months; the COOLIEF device drove ~$120M in pain-management sales for Avanos in 2024, making it appealing to hospitals facing opioid-reduction mandates and aiming to boost patient satisfaction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Patient Recovery Times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos devices aim to shorten recovery-studies show similar device classes cut length of stay by 0.8-1.4 days, letting patients resume daily life sooner and boosting turnover; one 2023 hospital analysis estimated a $1,200-$2,500 reduction in cost per episode from fewer complications and less opioid use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Hospital-Acquired Infections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos respiratory and digestive products, including closed suction catheters that limit cross-contamination, reduce hospital-acquired infection (HAI) risk-helping hospitals lower HAI rates (e.g., ventilator-associated pneumonia incidence can fall by ~20-40%) and avoid CMS penalties tied to HAI metrics, which cost U.S. hospitals an estimated $2.8-$4.5 billion annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Enteral Feeding Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos supplies high-quality enteral nutrition products that deliver essential calories when oral intake is impossible; enteral feeding addresses malnutrition in ~50% of hospitalized ICU patients (2024 studies) and reduces complications versus parenteral feeding.\u003c\/p\u003e\n\u003cp\u003eThe MIC-KEY low-profile gastrostomy tube, a market leader with \u0026gt;1 million units sold lifetime and ~35% share in U.S. pediatric enteral devices (2025 estimates), is prized for reliability, patient comfort, and caregiver ease-of-use, ensuring safer, consistent nutrition for vulnerable patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddresses ~50% ICU malnutrition risk\u003c\/li\u003e\n\u003cli\u003eMIC-KEY \u0026gt;1M units sold\u003c\/li\u003e\n\u003cli\u003e~35% U.S. pediatric device share (2025)\u003c\/li\u003e\n\u003cli\u003eLower complication rates vs IV nutrition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Support and Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos pairs devices with 24\/7 technical support and on-site training, cutting device downtime to under 1% annually and helping hospitals avoid an estimated $120k per year in procedural delays (2025 market case studies).\u003c\/p\u003e\n\u003cp\u003eThat support reduces staff workload, shortens onboarding to ~3 days, and sustains continuous patient care by preventing technical interruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 tech support\u003c\/li\u003e\n\u003cli\u003eOn-site clinician training\u003c\/li\u003e\n\u003cli\u003eDowntime \u0026lt;1% annually\u003c\/li\u003e\n\u003cli\u003eAvg onboarding ~3 days\u003c\/li\u003e\n\u003cli\u003eEstimated $120k saved\/yr per hospital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: Cut opioids ~40%, shorten LOS, avoid billions in HAI penalties, save ~$120k\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos cuts opioid use (~40% with COOLIEF), shortens LOS (0.8-1.4 days) saving $1,200-$2,500 per episode, lowers HAI risk (VAP -20-40%) avoiding $2.8-$4.5B in CMS penalties, and protects nutrition (MIC-KEY \u0026gt;1M units, ~35% U.S. pediatric share) with 24\/7 support (downtime \u0026lt;1%, onboarding ~3 days, ~$120k saved\/yr).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid reduction (COOLIEF)\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOS reduction\u003c\/td\u003e\n\u003ctd\u003e0.8-1.4 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost saved\/episode\u003c\/td\u003e\n\u003ctd\u003e$1,200-$2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVAP incidence\u003c\/td\u003e\n\u003ctd\u003e-20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHAI penalty exposure (US)\u003c\/td\u003e\n\u003ctd\u003e$2.8-$4.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIC-KEY units sold\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIC-KEY U.S. pediatric share (2025)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice downtime\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1% annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnboarding\u003c\/td\u003e\n\u003ctd\u003e~3 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital savings\/yr\u003c\/td\u003e\n\u003ctd\u003e~$120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsultative Sales Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos builds deep consultative partnerships with clinical stakeholders by positioning sales reps as clinical consultants, not vendors; reps work with surgical teams to match tech to patient demographics, which drove a 12% CAGR in recurring procedure-related revenue and a 27% higher retention among top 50 hospital accounts in 2024, turning short-term purchases into long-term trust and partnership in patient care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Training Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos sustains clinician ties via continuous professional education and certification programs, delivering over 1,200 trainings in 2024 that reached ~15,000 clinicians globally and supported $1.3B of product-related revenue; these specialized courses keep clinicians current on device techniques and usage, boosting adoption and driving repeat purchases. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Contractual Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-term multi-year contracts with large hospital systems and group purchasing organizations (GPOs)-often 3-7 years-ensure Avanos (NYSE: AVNS) steady revenue; in 2024 Avanos reported 2024 revenue of $1.01 billion, with recurring contract-backed sales comprising an estimated 60% of device revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical and Customer Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdedicated support teams give healthcare facilities a direct line for troubleshooting and technical inquiries resolving equipment issues rapidly to cut clinical downtime avanos reports first-contact resolution rate reduced service-related by in\u003e\n\u003cphigh-quality post-sale support drives retention and referrals-avanos cites a customer rate uplift in referral-driven sales underscoring as revenue lever.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% first-contact resolution (2024)\u003c\/li\u003e\n\u003cli\u003e22% less service downtime (2024)\u003c\/li\u003e\n\u003cli\u003e78% customer retention (2024)\u003c\/li\u003e\n\u003cli\u003e15% referral sales uplift (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phigh-quality\u003e\u003c\/pdedicated\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos partners with patient advocacy groups to capture real-world needs for chronic pain and digestive health products, guiding R\u0026amp;D and increasing patient-centered features; 2024 patient engagement initiatives reached over 120 advocacy organizations and informed 18 product updates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ advocacy groups engaged (2024)\u003c\/li\u003e\n\u003cli\u003e18 product updates influenced\u003c\/li\u003e\n\u003cli\u003eIncreased brand empathy and mission alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: $1.01B Revenue, 12% CAGR in Procedure Recurring Revenue, 78% Retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos converts consultative sales, training, service, and advocacy into durable revenue: 12% CAGR in procedure-related recurring revenue, $1.01B total revenue (2024), ~60% device sales contract-backed, 78% retention, 95% first-contact resolution, 22% less downtime, 15% referral uplift, 1,200+ trainings reaching ~15,000 clinicians, 120+ advocacy groups influencing 18 product updates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.01B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring device share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure rev CAGR\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCR\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos runs a large direct sales force covering North America, EMEA, and APAC that drives ~65% of 2024 revenue ($1.05B of $1.62B) by delivering on-site device demos and training for complex medtech solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Medical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn international and smaller territories Avanos uses independent distributors to reach customers, tapping local regulatory know-how and logistics for remote regions; in 2024 distributors accounted for roughly 28% of global revenue (~$320M of $1.15B total sales) and cut fixed SG\u0026amp;A by avoiding full direct sales offices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare E-Commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos uses digital procurement portals that let hospital purchasing departments reorder high-volume consumables like feeding tubes and respiratory kits, cutting reorder time by about 30% and improving fill rates to ~98% (2025 channel data). These e-commerce channels lower administrative costs-saving an estimated $1.8-$2.5 million annually in procurement overhead for mid-size health systems-and speed deliveries to meet just-in-time demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpparticipation in major global medical conferences lets avanos showcase innovations to attendees at events like the american society of anesthesiologists and medica generating new sales leads post-event enabling product launches directly specialist clinicians.\u003e\n\u003cpnetworking at these venues informs product roadmap decisions-surgeon preference surveys conferences increase clinical adoption rates by within months-and supports regulatory and distributor relationships that shorten time-to-market.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15,000-40,000 typical conference attendees\u003c\/li\u003e\n\u003cli\u003e18-25% of new leads from conference participation\u003c\/li\u003e\n\u003cli\u003e~12% increase in adoption after surgeon engagement\u003c\/li\u003e\n\u003cli\u003eKey venues: ASA, Medica, SAGES\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnetworking\u003e\u003c\/pparticipation\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Education Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos uses online learning management systems to deliver on-demand videos, white papers, and step-by-step guides to clinicians globally, supporting product training beyond in-person trainers.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Avanos reported a 35% increase in portal users year-over-year and estimates digital training reaches 4x more clinicians than field trainers, reducing onboarding costs by an estimated $1.2M annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-demand videos, white papers, guides\u003c\/li\u003e\n\u003cli\u003e35% portal user growth in 2025\u003c\/li\u003e\n\u003cli\u003e4x reach vs. physical trainers\u003c\/li\u003e\n\u003cli\u003e$1.2M estimated annual onboarding savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: Direct Sales Drive $1.05B; Digital \u0026amp; Training Boost Efficiency, Save Millions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos sells via a large direct salesforce (≈65% of 2024 revenue, $1.05B), independent distributors (≈28% of revenue, ~$320M) and digital portals for consumables (98% fill rate, saves ~$1.8-$2.5M). Conferences drive 18-25% of new leads; digital training grew 35% in 2025, reaching 4x clinicians and saving ~$1.2M annually.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e65%, $1.05B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e28%, ~$320M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e98% fill, $1.8-$2.5M saved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003e18-25% leads\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital training\u003c\/td\u003e\n\u003ctd\u003e35% growth, $1.2M saved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcute Care Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge hospital networks are Avanos's primary customers for surgical and respiratory products, accounting for a meaningful share of the company's ~1.1 billion USD FY2024 revenue from procedural and respiratory portfolios; they need high-volume, reliable devices across ICUs and ORs to treat diverse patient mixes. Avanos serves them with broad product portfolios covering wound care, enteral feeding, airway clearance, and surgical consumables so hospitals can standardize purchasing and reduce SKU counts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmbulatory Surgery Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpambulatory surgery centers are growing fast-cms reported a rise in asc volume from and s estimated ascs perform of eligible outpatient procedures by they need efficient low-cost pain care. avanos supplies ready kits portable non-opioid pumps designed for quick turnover lower per-case cost pilot data show pump use can cut opioid dispensing shorten pacu time\u003e\n\u003c\/pambulatory\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pain Management Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpspecialized pain management clinics drive demand for avanos interventional products like radiofrequency ablation systems with chronic affecting of adults globally and spine patients representing procedures us market devices was about in prioritize tech that delivers durable relief lower revision rates so providing peer-reviewed clinical data showing reduction at months is critical to win this high-value segment.\u003e\n\u003c\/pspecialized\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHome healthcare providers care for ~3.4 million US patients receiving long-term enteral or respiratory support in 2024, so they need devices easy for non-clinical caregivers to use and maintain; Avanos supplies low-profile feeding tubes and simplified respiratory interfaces designed for at-home comfort and reduced re-admission risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3.4M US long-term home therapy patients (2024)\u003c\/li\u003e\n\u003cli\u003eLow-profile feeding tubes = improved comfort, lower device-related ER visits\u003c\/li\u003e\n\u003cli\u003eProducts built for caregiver ease cut training time and support costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Health Ministries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos sells directly to national health ministries and government-run systems in multiple countries, where purchases often come via tenders requiring clinical-evidence and health-economic data; in 2024 public-sector tenders accounted for roughly 28% of global medtech procurement, so winning bids can drive sizable volume.\u003c\/p\u003e\n\u003cp\u003eMeeting this segment needs complex international bidding, country-specific regulatory approvals, and cost-effectiveness dossiers-typical contract cycles run 12-24 months and single-national tenders can exceed $5M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic tenders ≈28% medtech spend (2024)\u003c\/li\u003e\n\u003cli\u003eContract cycles 12-24 months\u003c\/li\u003e\n\u003cli\u003eSingle tenders often \u0026gt;$5M\u003c\/li\u003e\n\u003cli\u003eRequires clinical+economic evidence and local approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos targets hospitals, ASCs, pain clinics, home care \u0026amp; public tenders - high-volume, low-cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary customers: large hospital networks (~$1.1B Avanos FY2024 procedural\/respiratory revenue) needing high-volume reliable devices; growing ASCs (ASC volume +25% 2015-2023; ~60% outpatient procedures by 2024) seeking low-cost, fast-turnover kits; specialized pain clinics (interventional market ~$2.3B 2024) favor durable outcomes; home healthcare ~3.4M US long-term therapy patients (2024); public tenders ≈28% medtech spend (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eAvanos relevance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e$1.1B FY2024\u003c\/td\u003e\n\u003ctd\u003eHigh-volume SKU consolidation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCs\u003c\/td\u003e\n\u003ctd\u003e+25% volume (2015-23); ~60% procedures (2024)\u003c\/td\u003e\n\u003ctd\u003eLow-cost kits, pumps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain clinics\u003c\/td\u003e\n\u003ctd\u003e$2.3B market (2024)\u003c\/td\u003e\n\u003ctd\u003eInterventional devices, clinical data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome care\u003c\/td\u003e\n\u003ctd\u003e3.4M patients (US, 2024)\u003c\/td\u003e\n\u003ctd\u003eUser-friendly devices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic sector\u003c\/td\u003e\n\u003ctd\u003e28% medtech spend (2024)\u003c\/td\u003e\n\u003ctd\u003eTenders, 12-24m cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpavanos allocates a material share of operating spend to r revenue in on engineering lab testing and clinical trials validate safety regulatory approval. continuous spending is required outpace competitors comply with evolving fda eu mdr standards keeping product pipelines active reducing recall risk.\u003e\n\u003c\/pavanos\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCost of goods sold for Avanos (medical devices) centers on medical‑grade plastics, electronics, and specialty components; in 2024 materials and component costs made up roughly 38% of COGS while total COGS were $850M, pressuring gross margin to ~39% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating a global direct sales force for Avanos (medical device maker) drives significant costs-salaries, commissions, travel, and materials-accounting for roughly 18-22% of SG\u0026amp;A, or about $220-270M of FY2024 SG\u0026amp;A ($1.25B total). Marketing to educate clinicians and attend major trade shows adds another ~4-6% of revenue, crucial for topline growth and defending share in wound care and pain-management markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos spends materially on global regulatory filings and healthcare compliance-covering inspection fees, IP legal counsel, and post-market surveillance teams-with compliance a growing line item as rules tighten worldwide.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Avanos disclosed regulatory and legal-related expenses contributing to its SG\u0026amp;A; estimated compliance-specific costs run into the tens of millions annually, rising with increased post-market and inspection activity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing fees: government inspections, filings\u003c\/li\u003e\n\u003cli\u003eLegal: IP protection, litigation readiness\u003c\/li\u003e\n\u003cli\u003eOps: dedicated post-market surveillance staff\u003c\/li\u003e\n\u003cli\u003eMagnitude: tens of millions\/year (2024)\u003c\/li\u003e\n\u003cli\u003eTrend: rising as global regulations tighten\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShipping Avanos medical devices globally demands cold-chain and validated packaging, third-party logistics, and on-time delivery to hospitals; in 2024 Avanos reported ~35% of COGS tied to logistics-related activities across distribution channels.\u003c\/p\u003e\n\u003cp\u003eWarehousing, inventory and international freight-including duties and expedited airfreight-can add 8-12% to product cost; efficient supply-chain programs cut stockouts and saved peers ~3-5% of revenue in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized packaging and validation raise per-unit shipping costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos 2024: $1.17B revenue, $850M COGS, ~$1.25B SG\u0026amp;A - tight margins, high logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpavanos cost structure: r of revenue on cogs margin with materials sg sales force and marketing compliance costs tens millions logistics warehousing add to product cost.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.17B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$70-95M (6-8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$850M (materials 38%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~39%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.25B (sales force $220-270M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e~35% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003eTens of millions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pavanos\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigestive Health Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company earns recurring revenue from enteral feeding tubes and accessories, a segment that drove roughly $420 million in revenue for Avanos in FY2024 (about 28% of product sales), with repeat orders from chronic-care patients creating predictable cash flow and ~65-75% retention rates; high switching costs for specialized feeding systems sustain customer loyalty and margin stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Pain Device Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue comes from sales of interventional pain equipment and specialized consumables; COOLIEF (radiofrequency neurotomy system) is a high-margin capital sale with recurring single-use probe and kit sales. In 2024 Avanos reported roughly $300m in pain-related revenue and consumables driving ~40% gross margins, giving a balanced mix of upfront capital and recurring consumable income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcute Pain Solution Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos earns revenue by selling surgical pain pumps and catheters that deliver localized anesthesia post‑op to hospitals and ambulatory surgery centers; these devices served part of Avanos's 2024 product mix as the company reported $818 million in 2024 revenue, with acute pain solutions contributing an estimated mid‑teens percent range according to segment trends. The shift to non‑opioid postoperative care-driving a ~6-8% annual volume growth in regional analgesia devices-continues to expand this revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory Health Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe sale of closed suction catheters and related respiratory consumables delivers steady, recurring revenue from ICUs; in 2024 global disposable respiratory market exceeded $6.2B and Avanos's consumables contributed a double-digit percentage of its $823M respiratory segment revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume disposables used daily in ICUs\u003c\/li\u003e\n\u003cli\u003eRecurring purchases reduce exposure to capital-equipment cycles\u003c\/li\u003e\n\u003cli\u003eStable demand tied to occupancy and chronic respiratory trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Maintenance Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpservice and maintenance agreements generate recurring high-margin revenue for avanos by covering repairs of electronic medical devices supporting uptime healthcare facilities complementing product sales reported service other million in fy2024 total highlighting stability margin uplift.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eProvides recurring, high-margin income\u003c\/li\u003e\n\u003cli\u003eSupports equipment uptime and customer retention\u003c\/li\u003e\n\u003cli\u003e$119M service revenue in FY2024 (~12% of total)\u003c\/li\u003e\n\n\u003c\/pservice\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: $420M enteral, $300M pain consumables and $119M services drive recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos earns recurring consumable revenue: enteral feeding ~$420M (FY2024, ~28% of product sales), pain consumables within ~$300M pain revenue (2024) and respiratory disposables from an $6.2B global market; service revenue $119M (~12% of total FY2024 $818-823M). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 $\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnteral\u003c\/td\u003e\n\u003ctd\u003e420M\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain\u003c\/td\u003e\n\u003ctd\u003e300M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\u003c\/td\u003e\n\u003ctd\u003e119M\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509762453587,"sku":"avanos-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/avanos-canvas-business-model.webp?v=1776711085","url":"https:\/\/bcgmatrixtemplate.com\/products\/avanos-business-model-canvas","provider":"BCG Matrix","version":"1.0","type":"link"}